Roy J, Guidoin R, Martin L, Lephat H, Blais P, Marois M, Gagnon D, Awad J
Res Exp Med (Berl). 1980;176(3):219-34. doi: 10.1007/BF01855842.
Complications arising from difficulty controlled bleeding and thrombus formation during procedures which require extracorporeal circulation with heparin as anticoagulant motivate the search for better hemostasis and anticoagulant technology. An enzyme (Defibrase), having a specific interaction with fibrinopeptide A such as to cause fibrin depletion in a soluble form, has been proposed as an alternative to heparin. Defibrase, in contrast to heparin, does not affect blood platelet function. Heparin and Defibrase as anticoagulants were compared in 8 h perfusion studies using arterio-venous extracorporeal blood circuits in dogs; the circuitry included pumps, membrane oxygenators and filters serially. Thrombus formation, in the filters and the oxygenators as well as pathology of the perfused animal were investigated. The results suggest that defibrase-like enzymes have potential for enhanced control of hemorrhagic and thrombotic phenomena. Although impeded by a latency of several hours before the full anticoagulant properties are developed in vivo, it appears that enzymatically mediated defibrinogenation of blood may be a valuable alternative to heparinization in extracorporeal circulation procedures.
在需要以肝素作为抗凝剂进行体外循环的手术过程中，因出血难以控制和血栓形成而引发的并发症促使人们探寻更好的止血和抗凝技术。一种与纤维蛋白肽A具有特定相互作用从而使可溶性纤维蛋白消耗的酶（去纤酶）已被提议作为肝素的替代品。与肝素不同，去纤酶不影响血小板功能。在犬类的动静脉体外血液循环8小时灌注研究中对肝素和去纤酶作为抗凝剂进行了比较；该循环系统依次包括泵、膜式氧合器和过滤器。对过滤器和氧合器中的血栓形成以及灌注动物的病理学进行了研究。结果表明，类去纤酶具有增强控制出血和血栓形成现象的潜力。尽管在体内充分发挥抗凝特性之前会有几个小时的延迟，但血液的酶介导去纤维蛋白原作用似乎可能是体外循环手术中肝素化的一种有价值的替代方法。
